Roche’s Phase IIb study of prasinezumab missed primary endpoint, but suggests possible benefit in early-stage Parkinson’s disease
December 19, 2024 01:00 ET
|
F. Hoffmann-La Roche Ltd
PADOVA study showed numerical delay in motor progression and positive trends on multiple secondary and exploratory endpointsPrasinezumab continues to be well tolerated and no new safety signals were...
Roche transforms mass spectrometry diagnostics with launch of cobas® Mass Spec solution
December 18, 2024 01:00 ET
|
F. Hoffmann-La Roche Ltd
Roche launches its cobas® Mass Spec solution, bringing mass spectrometry to the routine clinical labClinical mass spectrometry testing offers unparalleled sensitivity and specificity, providing...
Roche’s Vabysmo prefilled syringe (PFS) approved in the EU for three retinal conditions that can cause blindness
December 13, 2024 01:10 ET
|
F. Hoffmann-La Roche Ltd
Vabysmo PFS is the first and only prefilled syringe containing a bispecific antibody, offering a convenient alternative to currently available Vabysmo vialsVabysmo has demonstrated rapid and robust...
Roche receives CE Mark for new and updated molecular cobas 6800/8800 systems, enhancing laboratory efficiency and testing capabilities
December 13, 2024 01:00 ET
|
F. Hoffmann-La Roche Ltd
The new cobas 6800/8800 systems 2.0 enhances throughput, run flexibility, enables sample prioritisation and is available as an upgrade to existing systems in healthcare settings around the...
New and updated data for Roche's fixed-duration Columvi and Lunsumio at ASH 2024 reinforce their potential to improve outcomes for people with lymphoma
December 10, 2024 01:00 ET
|
F. Hoffmann-La Roche Ltd
Long-term data confirm fixed-duration Columvi and Lunsumio achieve durable remissions beyond the end of treatment, with real-world data suggesting reduced treatment-related travel burden due to less...
Roche commences tender offer for all shares of Poseida Therapeutics, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right for up to $4.00 per share in cash
December 09, 2024 16:30 ET
|
F. Hoffmann-La Roche Ltd
Basel, 9 December 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has commenced a tender offer for all of the outstanding shares of common stock of Poseida Therapeutics, Inc....
Five-year results confirm Roche’s Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma
December 08, 2024 12:30 ET
|
F. Hoffmann-La Roche Ltd
Exploratory long-term follow-up analysis of the phase III POLARIX study indicated a positive trend in overall survival in favour of Polivy in combination with R-CHP for people with first-line diffuse...
FDA accepts supplemental Biologics License Application for Roche’s Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma
December 05, 2024 01:00 ET
|
F. Hoffmann-La Roche Ltd
Application is based on data from the phase III STARGLO study where Columvi plus chemotherapy showed a statistically significant and clinically meaningful improvement in overall survival1,2 This...
Roche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies
November 26, 2024 01:10 ET
|
F. Hoffmann-La Roche Ltd
Acquisition supports Roche’s Pharma Strategy and allows for a range of potentially first and best-in-class therapies across oncology, immunology, and neurology, uniquely positioning Roche in the new...
Roche reports update on Phase III SKYSCRAPER-01 study results
November 26, 2024 01:00 ET
|
F. Hoffmann-La Roche Ltd
Basel, 26 November 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) reports an update on the phase III SKYSCRAPER-01 study, evaluating tiragolumab combined with Tecentriq® (atezolizumab) compared to...